Related Experiment Videos
Genomic instability and tolerance to alkylating agents
1Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Hertfordshire.
Abstract:
Experimental models clearly indicate that the cytotoxic effects of the chemotherapeutic methylating agents are mediated by incomplete processing of one of the common DNA methylation products, O6-meGua. These attempts at processing persistent O6-meGua are by DNA mismatch repair, and resistance to methylating agents frequently arises through loss of this pathway. It is to be expected that mismatch repair defects will be found among cells that have developed clinical resistance to agents such as temozolomide and the methyltriazines. The selective sensitivity of mismatch repair defective cells to chloroethylating agents may have a direct applicability to clinical practice and offers real promise of effective chemotherapy for the substantial number of human tumours that show microsatellite instability. As for the mechanisms of human mismatch repair, the complexity of the early steps of the pathway(s) is underlined by the likely participation of multiple heterodimers in the mismatch recognition steps. just as different types of mismatch may be processed by distinct branches of the same pathway, the same may be true for different types of DNA damage.
Insights
DNA mismatch repair defects cause resistance to methylating chemotherapy agents. However, these defects make cancer cells sensitive to chloroethylating agents, offering new treatment strategies for microsatellite instability tumors.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Cytotoxic effects of methylating chemotherapy agents stem from unrepaired O6-methylguanine (O6-meGua) DNA adducts.
- DNA mismatch repair (MMR) pathway attempts to process O6-meGua, and its deficiency is a common mechanism of resistance to methylating agents.
Purpose of the Study:
- To investigate the role of DNA mismatch repair (MMR) in resistance to methylating agents.
- To explore the potential of targeting MMR-deficient cells with specific chemotherapeutic agents.
Main Methods:
- Utilized experimental models to study the cytotoxic effects of methylating agents.
- Analyzed the mechanisms of DNA mismatch repair (MMR) in the context of chemotherapy resistance.
Main Results:
- Loss of DNA mismatch repair (MMR) pathway function leads to resistance against methylating chemotherapeutic agents like temozolomide.
- Cells deficient in MMR exhibit selective sensitivity to chloroethylating agents.
Conclusions:
- MMR defects are implicated in clinical resistance to methylating agents.
- Targeting MMR-deficient tumors, characterized by microsatellite instability, with chloroethylating agents presents a promising therapeutic strategy.